Endometrial Cancer

The Healio Editors compiled a list of recent news from the Society of Gynecologic Oncology Annual Meeting held from March 25-28, 2023.

Dostarlimab plus carboplatin significantly increased PFS among women with primary advanced or recurrent endometrial cancer, according to study results presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The addition of pembrolizumab to chemotherapy significantly extended PFS for women with advanced or recurrent endometrial cancer, according to study results presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The FDA granted regular approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.

The addition of pembrolizumab to chemotherapy significantly extended PFS as first-line treatment for advanced or recurrent endometrial carcinoma, according to the agent’s manufacturer.

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

A combination of dostarlimab-gxly and standard-of-care chemotherapy significantly extended PFS compared with placebo and chemotherapy among women with primary advanced or recurrent endometrial cancer, topline data showed.

A greater number of live births causally reduced the risk for endometrial cancer, according to study results published in BMC Medicine.

An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.

Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors in 75% of patients with recurrent or persistent estrogen receptor-positive, or ER-positive, endometrial cancer.